Thalidomide in multiple myeloma

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 2, 2006, Pages 195-213

  García Sanz, Ramón ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Anti angiogenic drugs; Immunomodulatory drugs; Lymphoproliferative disorders; Monoclonal component; Multiple myeloma; Plasma cell dyscrasias; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; EPIRUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

ATRIOVENTRICULAR BLOCK; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; BRADYCARDIA; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ERYTHEMA; ERYTHEMA MULTIFORME; GRANULOCYTOPENIA; HUMAN; HYPERESTHESIA; HYPOTHYROIDISM; INFECTION; LIVER DYSFUNCTION; MOOD DISORDER; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; NAIL DISEASE; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUDDEN DEATH; TERATOGENICITY; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VENOUS THROMBOEMBOLISM; XEROSTOMIA;

HUMANS; MULTIPLE MYELOMA; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 33144456575     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.2.195     Document Type: Review

References (183)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer Statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
2. GAHRTON G, DURIE BG, SAMSON D: Multiple myeloma and related disorders. Arnold Publishers, London (2005).
3. ALEXANIAN R, HAUT A, KHAN AU et al.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 208(9):1680-1685.
4. MYELOMA TRIALISTS' COLLABORATIVE GROUP: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol. (1998) 16(12):3832-3842.
5. MCELWAIN TJ, POWLES RL: High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet (1983) 2(8354):822-824.
6. CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple mycloma. N. Engl. J. Med. (2003) 348(19):1875-1883.
7. ATTAL M, HAROUSSEAU JL, STOPPA AM et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. (1996) 335(2):91-97.
8. BLADE J, ROSINOL L, SUREDA A et al.: High-dose therapy intensification versus continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood (2005) 106(12):3755-3759.
9. FERMAND JP, RAVAUD P, CHEVRET S et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood (1998) 92(9):3131-3136.
10. SAN MIGUEL JF, GARCIA-SANZ R: Myeloma: update on supportive care strategies. Curr. Treat. Options. Oncol (2003) 4(3):247-258.
11. TANSEY EM: Dark remedy: the impact of thalidomide and its revival as a vital medicine. N. Engl. J. Med. (2001) 345(3):226-227.
12. SOMERS G: Pharmacologic properties of thalidomide (∼ -phthalimido glutarimide), a new sedative hypnotic drug. Br. Pharmacol. (1960) 15:111-116.
13. MCBRIDE WG: Thalidomide and congenital abnormalities. Lancet (1961) 2:1358.
14. MOLLER DR, WYSOCKA M, GREENLEE BM et al.: Inhibition of IL-12 production by thalidomide. J. Immunol. (1997) 159(10):5157-5161.
15. SAMPAIO EP, KAPLAN G, MIRANDA A et al.: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. (1993) 168(2):408-414.
16. WEBER D: Lenalinomide (CC-5013, Revlimid) and other Imids. Haematologica (2005) 90(s1):24-25. Abstract PL5.02.
17. GIBSON AD, KLEM J, PRICE N et al.: 45th Annual Meeting of the American Society of Hematology December 6-9, 2003. Clin. Lymphoma (2004) 4(4):206-212.
18. RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
19. WU JJ, HUANG DB, PANG KR et al.: Thalidomide: dermatological indications, mechanisms of action and side-effects. Br. J. Dermatol. (2005) 153(2):254-273.
20. MATTHEWS SJ, MCCOY C: Thalidomide: a review of approved and investigational uses. Clin. Ther. (2003) 25(2):342-395.
21. CELGENE CORPORATION: Thalomid® (thalidomide capsules) prescribing information. Celgene Corporation, Summit (NJ) USA (2005).
22. ERIKSSON T, BJORKMAN S, ROTH B et al.: Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality (1998) 10(3):223-228.
23. WINTER W, FRANKUS E: Thalidomide enantiomers. Lancet (1992) 339(8789):365.
24. ERIKSSON T. BJORKMAN S, ROTH B et al.: Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J. Pharm. Pharmacol. (2000) 52(7):807-817.
25. HOGLUND P, ERIKSSON T, BJORKMAN S: A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J. Pharmacokinet. Biopharm. (1998) 26(4):363-383.
26. BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its imid derivatives as anticancer agents. Nat. Rev. Cancer (2004) 4(4):14-322.
27. TEO SK, COLBURN WA, TRACEWELL WG et al.: Clinical pharmacokinetics of thalidomide. Clin. Pharmacokinet. (2004) 43(5):311-327.
28. TEO SK, COLBURN WA, THOMAS SD: Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J. Clin. Pharmacol. (1999) 39(11):1162-1168.
29. TEO SK, SABOURIN PJ, O'BRIEN K et al.: Metabolism of thalidomide in human microsomes, cloned human cytochrome P450 isozymes, and Hanser's disease patients. J. Biochem. Mol. Toxicol. (2000) 14(3):140-147.
30. DIMOPOULOS MA, ANAGNOSTOPOULOS A, WEBER D: Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J. Clin. Oncol. (2003) 21(23):4444-4454.
31. DAMATO RJ, LOUGHNAN MS, FLYNN E et al.: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082-4085.
32. KENYON BM, BROWNE F, D'AMATO RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64(6):971-978.
33. LENTZSCH S, ROGERS MS, LEBLANC R et al.: S-3-Aminophthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. (2002) 62(8):2300-2305.
34. VACCA A, RIBATTI D, RONCALI L et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. (1994) 87(3):503-508.
35. GUALANDRIS A, URBINATI C, RUSNATI M et al.: Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. J. Cell. Physiol. (1994) 161(1):149-159.
36. PITTINI V, TETI D, ARRIGO C et al.: Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFG F. Br. J. Haematol. (2002) 119(1):275.
37. VACCA A, RIA R, SEMERARO F et al.: Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 102(9):3340-3348.
38. VACCA A, RIBATTI D, PRESTA M et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 93(9):3064-3073.
39. PAYVANDI F, WU L, HALEY M et al.: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell. Immunol. (2004) 230(2):81-88.
40. ZHANG M, ABE Y, MATSUSHIMA T et al.: Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leuk. Lymphoma (2005) 46(3):425-433.
41. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. (1999) 341(21):1565-1571.
42. NEBEN K, MOEHLER T, KRAEMER A et al.: Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br. J. Haematol. (2001) 115(3):605-608.
43. KUMAR S, WITZIG TE, DISPENZIERI A et al.: Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia (2004) 18(3):624-627.
44. ZHANG H, VAKIL V, BRAUNSTEIN M et al.: Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood (2005) 105(8):3286-3294.
45. HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96(9):2943-2950.
46. LENTZSCH S, LEBLANC R, PODAR K et al.: Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia (2003) 17(1):41-44.
47. MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99(12):4525-4530.
48. MEIERHOFER C, WIEDERMANN CJ: New insights into the pharmacological and toxicological effects of thalidomide. Curr. Opin. Drug Discov. Devel. (2003) 6(1):92-99.
49. GUPTA D, TREON SP, SHIMA Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 15(12):1950-1961.
50. SETTLES B, STEVENSON A, WILSON K et al.: Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol. Biol. (2001) 47(7):1105-1114.
51. GEITZ H, HANDT S, ZWINGENBERGER K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 31(2-3):213-221.
52. ZWINGENBERGER K, WNENDT S: Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflamm. (1995) 46(4):177-211.
53. TURK BE, JIANG H, LIU JO: Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc. Natl. Acad. Sci. USA (1996) 93(15):7552-7556.
54. RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Ann. Rev. Med. (2002) 53:629-57:629-657.
55. DUNZENDORFER S, HEROLD M, WIEDERMANN CJ: Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide. Immunopharmacology (1999) 43(1):59-64.
56. OLIVER SJ: The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide. Curr. Rheumatol. Rep. (2000) 2(6):486-491.
57. SHANNON EJ, SANDOVAL F: Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology (1995) 31(1)109-116.
58. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163(1):380-386.
59. KEIFER JA, GUTTRIDGE DC, ASHBURNER BP et al.: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. (2001) 276(25):22382-22387.
60. MITSIADES N, MITSIADES CS, POULAKI V et al: Biologic sequclae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood (2002) 99(11):4079-4086.
61. DAVIES FE, RAJE N, HIDESHIMA T et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood(2001) 98(1):210-216.
62. HASLETT PA, HANEKOM WA, MULLER G et al.: Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J. Infect. Dis. (2003) 187(6):946-955.
63. HAYASHI T, HIDESHIMA T, AKIYAMA M et al.: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. (2005) 128(2):192-203.
64. HASLETT PA, CORRAL LG, ALBERT M et al.: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. (1998) 187(11):1885-1892.
65. CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. (1999) 163(1):380-386.
66. ATTIGA FA, FERNANDEZ PM, WEERARATNA AT et al.: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. (2000) 60(16):4629-4637.
67. HUS M, DMOSZYNSKA A, KOCKI J et al.: Long-term thalidomide therapy resulted in lack of mdr1 gene expression in 2 patient with primary resistant multiple myeloma. Leukemia (2005) 19(8):1497-1499.
68. PEREZ-SIMON JA, VALVERDE B, MARTINEZ A et al.: Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma. Cytometry (1999) 38(1):24-29.
69. RAJKUMAR SV, BLOOD E, VESOLE DH et al.: Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood (2004) 104(11) Abstr. 205.
70. BARLOGIE B: Thalidomide and CC-5013 in multiple myeloma; the University of Arkansas experience. Semin. Hematol. (2003) 40(4 Suppl. 4) 33-38.
71. BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase II study of 169 patients. Blood (2001) 98(2):492-494.
72. HUS M, DMOSZYNSKA A, SOROKA-WOJTASZKO M et al.: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica (2001) 86(4):404-408.
73. HUS I, DMOSZYNSKA A, MANKO J et al.: An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br. J. Cancer (2004) 91(11):1873-1879.
74. GROSBOIS B, BELISSANT E, MOREAU P et al.: Treatment of advanced multiple myeloma with thalidomide: long term follow-up in a prospective study of 121 patients. Hematol. J. (2003) 4(Suppl. 1):S226.
75. NEBEN K, MOEHLER T, BENNER A et al.: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. (2002) 8(11):3377-3382.
76. YAKOUB-AGHA I, ATTAL M, DUMONTET C et al.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol. J. (2002) 3(4):185-192.
77. MILESHKIN L, BIAGI JJ, MITCHELL P et al.: Multicenter Phase II trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 102(1):69-77.
78. MURAKAMI H, HANDA H, IMAI K et al.: [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group]. Rinsho Ketsueki (2004) 45(6):468-472.
79. PETRUCCI MT, PALUMBO G, MARTINI V et al.: Thalidomide, an active agent for multiple myeloma does not change the prognosis of plasma cell leukemia patients. Experience of a single center. Hematol. J. (2003) 4(Suppl. 1):S227.
80. WU KL, SCHAAFSMA MR, LOKHORST HM et al.: [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned. Tijdschr. Geneeskd (2002) 146(31):1445-1448.
81. WU KL, HELGASON HH, VAN DER HB et al.: Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia (2005) 19(1):143-145.
82. WAAGE A, GIMSING P, JULIUSSON G et al.: Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br. J. Haematol. (2004) 125(2):149-155.
83. TOSI P, ZAMAGNI E, CELLINI C et al.: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica (2002) 87(4):408-414.
84. HUANG SY, TANG JL, YAO M et al.: Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann. Hematol. (2003) 82(9):558-564.
85. BLADE J, PERALES M, ROSINOL L et al.: Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br. J. Haematol. (2001) 113(2):422-424.
86. CIBEIRA MT, ROSINOL L, ESTEVE J et al.: Talidomide in refractory and relapsed multiple myeloma: duration of response. Haematologica (2005) 90(Suppl. 1): 140 Abstr.
87. KUMAR S, GERTZ MA, DISPENZIERI A et al.: Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin. Proc. (2003) 78(1):34-39.
88. MOHTY M, ATTAL M, MARIT G et al.: Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. (2005) 35(2):165-169.
89. WECHALEKAR AD, CHEN CI, SUTTON D et al.: Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk. Lymphoma (2003) 44(7):1147-1149.
90. JULIUSSON G, CELSING F, TURESSON I et al.: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br. J. Haematol. (2000) 109(1):89-96.
91. KEES M, DIMOU G, SILLABER C et al.: Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk. Lymphoma (2003) 44(11):1943-1946.
92. KNELLER A, RAANANI P, HARDAN I et al.: Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. Br. J. Haematol. (2000) 108(2):391-393.
93. RAJKUMAR SV, FONSECA R, DISPENZIERI A et al.: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin. Proc. (2000) 75(9):897-901.
94. RAJKUMAR SV, GERTZ MA, KYLE RA et al.: Current therapy for multiple myeloma. Mayo Clin. Proc. (2002) 77(8):813-822.
95. TOSI P, RONCONI S, ZAMAGNI E et al.: Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica (2001) 86(4):409-413.
96. ALEGRE A, AGUADO B, GIL-FERNÁNDEZ JJ et al.: Long-term treament with low dose thalidomide in multiple myeloma. Haematologica (2005) 90(Suppl. 1): 140 Abstr. PL.706.
97. ANAGNOSTOPOULOS A, HAMILOS G, ZORZOU MP et al.: Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk. Lymphoma (2004) 45(1):113-116.
98. DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol. (2001) 12(7):991-995.
99. PALUMBO A, GIACCONE L, BERTOLA A et al.: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica (2001) 86(4):399-403.
100. BOULIN M, BLANCHET F, ISAMBERT N et al.: [Thalidomide with or without dexamethasone for refractory multiple myeloma]. Therapie (2002) 57(6):524-529.
101. ALEXANIAN R, WEBER D, ANAGNOSTOPOULOS A et al.: Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin. Hematol. (2003) 40(4 Suppl. 4):3-7.
102. ANAGNOSTOPOULOS A, WEBER D, RANKIN K et al.: Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. (2003) 121(5):768-771.
103. PALUMBO A, BERTOLA A, FALCO P et al.: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol. J. (2004) 5(4):318-324.
104. TOSI P, ZAMAGNI E, CELLINI C et al.: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur. J. Haematol. (2004) 73(2):98-103.
105. CARAVITA T, SINISCALCHI A, SANTINELLI S et al.: Low dose thalidomide plus dexamethasone for relapsed/refractory multiple myeloma: a single center expèrience. Haemtol. J. (2003) 4(Suppl. 1):S237 Abstr. 333.
106. GARDYN J: Thalidomide with continuous low-dose dexamethasone for multiple myeloma. J. Clin. Oncol. (2005) 23(6):1323.
107. BARLOGIE B, ZANGARI M, SPENCER T et al.: Thalidomide in the management of multiple myeloma. Semin. Hematol. (2001) 38(3):250-259.
108. GARCIA-SANZ R, GONZALEZ-FRAILE MI, SIERRA M et al.: The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol. J. (2002) 3(1):43-48.
109. GARCIA-SANZ R, GONZALEZ-PORRAS JR, HERNANDEZ JM et al.: The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/ refractory multiple myeloma. Leukemia (2004) 18(4):856-863.
110. DIMOPOULOS MA, HAMILOS G, ZOMAS A et al.: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol. J. (2004) 5(2):112-117.
111. KYRIAXOU C, THOMSON K, D'SA S et al.: Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br.J. Haematol. (2005) 129(6):763-770.
112. DI RAIMONDO F, PENNISI A, BUGLIO D et al.: Combination of thalidomide, cyclophosphamide, and dexamethasone in refractory-relapsed multiple myeloma. Hematol. J. (2003) 4(Suppl. 1):S241 Abstr. 343.
113. KROPFF MH, LANG N, BISPING G et al.: Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br. J. Haematol. (2003) 122(4):607-616.
114. MOEHLER TM, NEBEN K, BENNER A et al.: Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 98(13):3846-3848.
115. HUSSEIN MA: Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist (2003) 8(Suppl. 3):39-45.
116. SRKALOVIC G, ELSON P, TREBISKY B et al.: Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med. Oncol. (2002) 19(4):219-226.
117. LEE CK, BARLOGIE B, MUNSHI N et al.: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. Oncol. (2003) 21(14):2732-2739.
118. HUSSEIN MA: New treatment strategies for multiple myeloma. Semin. Hematol. (2004) 41(4 Suppl. 7):2-8.
119. WEBER D, RANKIN K, GAVINO M et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol (2003) 21(1):16-19.
120. RAJKUMAR SV: Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Semin. Hematol. (2003) 40(4 Suppl. 4):17-22.
121. RAJKUMAR SV, GERTZ MA, LACY MQ et al.: Thalidomide as initial therapy for earlystage myeloma. Leukemia (2003) 17(4):775-779.
122. CAVO M, ZAMAGNI E, TOSI P et al.: First-line therapy with thalidomide and decamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica (2004) 89(7):826-831.
123. WANG M, WEBER DM, DELASALLE K et al.: Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am. J. Hematol. (2005) 79(3):194-197.
124. CAVO M, ZAMAGNI E, TOSI P et al.: Superiority of thalidomide and decamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood (2005) 106(1)35-39.
125. RAJKUMAR SV: Multiple myeloma: the death of VAD as initial therapy. Blood (2005) 106(1):2-3.
126. PALUMBO A, BERTOLA A, MUSTO P et al.: Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer (2005) 104(7):1428-1433.
127. ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E et al.: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. (2004) 15(1):134-138.
128. SCHUTT P, EBELING P, BUTTKEREIT U et al.: Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur. J. Haematol. (2005) 74(1):40-46.
129. OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med. (2001) 344(25):1951-1952.
130. ZANGARI M, ANAISSIE E, BARLOGIE B et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 98(5):1614-1615.
131. ZANGARI M, BARLOGIE B, ANAISSIE E et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br. J. Haematol. (2004) 126(5):715-721.
132. BARLOGIE B, RASMUSSEN E, SHAUGHNESSY J et al.: Total therapy for newly diagnosed multiple myeloma: the Arkansas Experience with 1000 patients treated with Total Therapy 1, 2 and 3. Haematologica (2005) 90(Suppl. 1):19 Abstr. PL4.04.
133. ALEXANIAN R, WEBER D, GIRALT S et al.: Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann. Oncol. (2002) 13(7):1116-1119.
134. SANTOS ES, GOODMAN M, BYRNES JJ et al.: Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology (2004) 9(1):35-39.
135. STEWART AK, CHEN CI, HOWSON-JAN K et al.: Results of a multicenter randomized Phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin. Cancer Res. (2004) 10(24):8170-8176.
136. ATTAL M, HAROUSSEAU JL, LEYVRAZ S et al.: Maintenance treatment with thalidomide and pamidronate after autologus transplantation for myeloma: Second analysis of a prospective randomized study of the intergroupe francophone du myeloma. Haematologica (2005) 90 (Suppl. 1): 17 Abstr. PL4.01.
137. DURIE BG: Low-dose thalidomide in myeloma. efficacy and biologic significance. Semin. Oncol. (2002) 29(6 Suppl. 17):34-38.
138. ALEXANIAN R, WEBER D: Thalidomide for resistant and relapsing myeloma. Semin. Hematol. (2005) 37(Suppl.):22-25.
139. KROGER N, SHIMONI A, ZAGRIVNAJA M et al.: Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood (2004) 104(10):3361-3363.
140. OFFIDANI M, CORVATTA L, MARCONI M et al.: Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur. J. Haematol. (2004) 72(6):403-409.
141. RIBAS C, COLLEONI G, ALMEIDA M et al.: Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. Acta Oncol. (2004) 43(2):215-216.
142. STEURER M, SPIZZO G, MITTERER M et al.: Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie (2004) 27(2):150-154.
143. JOHNSTON RE, ABDALLA SH: Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple mycloma and for plasma cell leukaemia. Leuk. Lympboma (2002) 43(2):351-354.
144. LELEU X, MAGRO L, FAWAZ A et al.: Efficacy of a low dose of thalidomide in advanced multiple myeloma. Blood (2002) 100(4):1519-1520.
145. LEE FC: Second response to lower-dose thalidomide in a patient with multiple myeloma. Blood (2002) 99(11):4248.
146. WAAGE A, ROMSTAD L, BRENNE AT: Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. Blood (2002) 100(1):380b.
147. OAKERVEE H, GUPTA V, SMITH. ML: Response to thalidomide can be predicted by paraprotein quantitation 14 days after initiating therapy. Br. J. Haematol. (2001) 113 (Suppl.):40.
148. NEBEN K, MOEHLER T, EGERER G et al.: High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res. (2001) 7(9):2675-2681.
149. NEBEN K, MYTILINEOS J, MOEHLER TM et al.: Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood (2002) 100(6):2263-2265.
150. THOMPSON MA, WITZIG TE, KUMAR S et al.: Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br. J. Haematol. (2003) 123(2):305-308.
151. SAMPAIO EP, HERNANDEZ MO, CARVALHO DS et al.: Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed, Pharmacother. (2002) 56(1):13-19.
152. NOORMOHAMED FH, YOULE MS, HIGGS CJ et al.: Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res. Hum. Retroviruses (1999) 15(12):1047-1052.
153. RAJKUMAR SV, GERTZ MA, WITZIG TE: Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N. Engl. J. Med. (2000) 343(13):972-973.
154. HALL VC, EL AZHARY RA, BOUWHUIS S et al.: Dermatologic side effects of thalidomide in patients with multiple myeloma. J. Am. Acad. Dermatol. (2003) 48(4):548-552.
155. BLADE J, ROSINOL L: Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies. Clin. Lymphoma (2003) 3(4):247-248.
156. FAHDI IE, GADDAM V, SAUCEDO JF et al.: Bradycardia during therapy for multiple myeloma with thalidomide. Am. J. Cardiol. (2004) 93(8):1052-1055.
157. BLADE J, ESTEVE J, ROSINOL L et al.: Thalidomide in refractory and relapsing multiple myeloma. Semin. Oncol. (2001) 28(6):588-592.
158. TOSI P, ZAMAGNI E, CELLINI C et al.: Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur. J. Haematol. (2005) 74(3):212-216.
159. BASTUJI-GARIN S, OCHONISKY S, BOUCHE P et al.: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J. Invest. Dermatol. (2002) 119(5):1020-1026.
160. MAURER T, PONCELET A, BERGER T: Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch. Dermatol. (2004) 140(7):845-849.
161. ISOARDO G, BERGUI M, DURELLI L et al.: Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol. Scand. (2004) 109(3):188-193.
162. CHAUDHRY V, CORNBLATH DR, CORSE A et al.: Thalidomide-induced neuropathy. Neurology (2002) 59(12):1872-1875.
163. MOLLOY FM, FLOETER MK, SYED NA et al.: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve (2001) 24(8):1050-1057.
164. OCHONISKY S, VERROUST J, BASTUJI-GARIN S et al.: Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. (1994) 130(1):66-69.
165. MARKARIAN Y, WULFF EA, SIMPSON DM: Peripheral neuropathy in HIV disease. AIDS Clin. Care (1998) 10(12):89-91,93,98.
166. FULLERTON PM, O'SULLIVAN DJ: Thalidomide neuropathy: a clinical electrophysiologica, and histological follow-up study. J. Neurol. Neurosurg. Psychiatry (1968) 31(6):543-551.
167. SRKALOVIC G, CAMERON MG, RYBICKI L et al.: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer (2004) 101(3):558-566.
168. BARLOGIE B, JAGANNATH S, DESIKAN KR et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 93(1):55-65.
169. RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. (2002) 20(21):4319-4323.
170. BOWCOCK SJ, RASSAM SM, WARD SM et al.: Thromboembolism in patients on thalidomide for myeloma. Hematology (2002) 7(1):51-53.
171. MOEHLER TM, HILLENGASS J, GOLDSCHMIDT H et al.: Antiangiogenic therapy in hematologic malignancies. Curr. Pharm. Des. (2004) 10(11):1221-1234.
172. ZANGARI M, SIEGEL E, BARLOGIE B et al.: Thrombogenic activity of doxorubicin, in myeloma patients receiving thalidomide: implications for therapy. Blood (2002) 100(4):1168-1171.
173. URBAUER E, KAUFMANN H, NOSSLINGER T et al.: Thromboembolic events during treatment with thalidomide. Blood (2002) 99(11):4247-4248.
174. HUSSEIN MA, KARAM MA, REED J et al.: Pegylated doxorubicin in combination with immune-moculators and arsenic-containing regimens for the management of multiple myeloma. Haematologica (2005) 90(Suppl. 1):25-26.
175. OSMAN K, COMENZO R, RAJKUMAR SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engt J. Med. (200 1) 344(25):1951-1952.
176. KAUSHAL V, KAUSHAL GP, MELKAVERI SN et al: Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost. (2004) 2(2):327-334.
177. MINNEMA MC, FIJNHEER R, DE GROOT PG et al.: Extremely high levels of von Willebrand factor antigen and of procoagulant Factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost. (2003) 1(3):445-449.
178. ZANGARI M, BARLOGIE B, THERTULIEN R et al.: Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin. Lymphoma (2003) 4(1):32-35.
179. WEBER D: Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control (2003) 10(5):375-383.
180. DE SAVARY N, LEE R, VAIDYA B: Severe hypothyroidism after thalidomide treatment. J. R. Soc. Med. (2004) 97(9):443.
181. BADROS AZ, SIEGEL E, BODENNER D et al.: Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am. J. Med. (2002) 112(5):412-413.
182. MURDOCH JM, CAMPBELL GD: Antithyroid activity of N-phthaloyl glutamic acid. Br. Med. J. (1958) 1:84-85.
183. DIMOPOULOS MA, ELEUTHERAKIS-PAPAIAKOVOU V: Adverse effects of thalidomide administration in patients with neoplastic diseases. Am. J. Med. (2004) 117(7):508-515.